文献速递其他结缔组织病

原发性干燥综合征B细胞标志物的稳定性与预后价值:法国ASSESS队列结果

Stability and prognostic value of B-cell markers in primary SS: results from the French ASSESS cohort.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

基于法国多中心前瞻性ASSESS队列362例符合AECG标准、随访≥2次且含免疫学评估与ClinESSDAI评分的原发性干燥综合征患者,分析B细胞标志物纵向演变及其与临床病程的关联。中位随访56.4个月,80.5%患者B细胞标志物保持稳定;基线B细胞异常标志物≥5个者持续或恶化风险增高(OR 4.6,95%CI 1.2-17.8;P=0.002)。

要点

  • 原发性干燥综合征患者B细胞标志物谱在随访中总体保持稳定,80.5%患者稳定。
  • 基线多种B细胞活动标志物尤其≥5个与持续或恶化疾病风险增高相关(OR 4.6)。
  • 按STAR生物学域标准43.1%为生物学应答者,多发生在第一年,与ClinESSDAI或ESSPRI变化无相关性。

核心结论

  • 原发性干燥综合征B细胞标志物谱长期总体稳定,但高基线B细胞负荷可识别预后较差风险患者,支持其用于分层和监测。

研究设计与样本

  • 法国多中心前瞻性ASSESS队列研究,纳入符合AECG标准、5年随访内≥2次就诊且含免疫学评估与ClinESSDAI评分的患者,共362例。
  • 基线B细胞标志物包括免疫球蛋白水平、单克隆成分、冷球蛋白血症、补体成分、类风湿因子和β2微球蛋白,采用ClinESSDAI评估疾病活动度。

主要发现

  • 362例患者平均随访56.4个月(±10.6),人均5.3次就诊(±0.5),80.5%患者B细胞标志物保持稳定。
  • 基线ClinESSDAI在不同B细胞异常数目间无差异(P=0.096)。
  • 多个B细胞活动标志物尤其≥5个者持续或恶化疾病风险增高(OR 4.6,95%CI 1.2-17.8;P=0.002)。
  • 按STAR标准基于IgG下降定义生物学应答者占43.1%,多发生在第一年,与ClinESSDAI或ESSPRI变化无相关性。

关键数值与推荐

  • B细胞标志物稳定定义为80.5%患者保持稳定。
  • STAR指数生物学域应答定义为IgG相对下降≥10%,43.1%患者符合。
  • 基线B细胞异常标志物≥5个与持续或恶化疾病风险相关(OR 4.6,95%CI 1.2-17.8;P=0.002)。

临床怎么用

  • 临床可检测基线B细胞标志物负荷,尤其≥5个异常标志物者提示持续或恶化疾病风险较高,可考虑加强分层与监测。
  • IgG下降虽可按STAR标准定义生物学应答,但未显示与ClinESSDAI或ESSPRI变化相关,解读时需结合整体疾病活动评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To characterize the longitudinal evolution of B-cell biomarkers in patients with primary Sjögren's disease (SjD) and analyse their association with the clinical disease course. METHODS: We analysed data from the French multicentre prospective ASSESS cohort. Patients fulfilling AECG criteria with ≥2 visits including both immunological assessments and ClinESSDAI scores over a 5 years follow-up were included. Baseline B-cell biomarkers included immunoglobulin levels, monoclonal component, cryoglobulinaemia, complement fractions, RF and β2-microglobulin. Disease activity was assessed using ClinESSDAI score. Associations between the number of abnormal B-cell markers and disease activity were analysed using ANOVA and Kruskal-Wallis tests. Changes in IgG were evaluated according to the biological domain of the STAR index, defined as a relative decrease ≥10%. RESULTS: Among the 395 ASSESS participants, 362 met inclusion criteria. Mean follow-up was 56.4 months (±10.6), with a mean of 5.3 visits per patient (±0.5). B-cell biomarkers remained stable in 80.5%. According to STAR criteria, 43.1% were classified as biological responders to the biological domain of STAR based on IgG decrease, occurring mostly within the first year, without correlation with changes in ClinESSDAI or ESSPRI. Although baseline ClinESSDAI did not differ by the number of B-cell abnormalities (P = 0.096), patients with multiple B-cell activity markers-particularly ≥5-had an increased risk of persistent or worsening disease (OR 4.6, 95% CI 1.2-17.8; P = 0.002). CONCLUSION: B-cell biomarkers profile in SjD is largely stable over time. However, a high baseline 'B-cell burden' identifies patients at risk of poorer outcomes, supporting their use for stratification and monitoring.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Szafors P, Lukas C, Combe B, et al. Stability and prognostic value of B-cell markers in primary SS: results from the French ASSESS cohort. Rheumatology (Oxford). 2026. PMID: 42384910. doi:10.1093/rheumatology/keag339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。